MedTrace Logo

Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens

NCT00218127 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2017-01-12

No results posted yet for this study

Summary

Heroin dependence remains a major addiction problem in the United States. The purpose of this study is to determine the effectiveness of levoacetyl methadol (ORLAAM) in treating heroin dependent individuals.

Conditions

  • Heroin Dependence
  • Opioid-Related Disorders

Interventions

DRUG

Levoacetyl Methadol

WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day

DRUG

Levoacetyl Methadol

MaxEffect+CBT evaluation to 48 mg Adjust to effect (+/-)

DRUG

Levoacetyl Methadol

LAAM Fixed Dose evaluation up to 48 mg 48 mg

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • John Grabowski, PhD · The University of Texas Health Science Center, Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-11-30
Primary Completion
2005-07-31
Completion
2005-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00218127 on ClinicalTrials.gov